FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313502805> ?p ?o ?g. }

• W4313502805 endingPage "69" @default.
• W4313502805 startingPage "69" @default.
• W4313502805 abstract "Chemotherapy is the main treatment for most early-stage cancers; nevertheless, its efficacy is usually limited by drug resistance, toxicity, and tumor heterogeneity. Cell-penetrating peptides (CPPs) are small peptide sequences that can be used to increase the delivery rate of chemotherapeutic drugs to the tumor site, therefore contributing to overcoming these problems and enhancing the efficacy of chemotherapy. The drug combination is another promising strategy to overcome the aforementioned problems since the combined drugs can synergize through interconnected biological processes and target different pathways simultaneously. Here, we hypothesized that different peptides (P1–P4) could be used to enhance the delivery of chemotherapeutic agents into three different cancer cells (HT-29, MCF-7, and PC-3). In silico studies were performed to simulate the pharmacokinetic (PK) parameters of each peptide and antineoplastic agent to help predict synergistic interactions in vitro. These simulations predicted peptides P2–P4 to have higher bioavailability and lower Tmax, as well as the chemotherapeutic agent 5-fluorouracil (5-FU) to have enhanced permeability properties over other antineoplastic agents, with P3 having prominent accumulation in the colon. In vitro studies were then performed to evaluate the combination of each peptide with the chemotherapeutic agents as well as to assess the nature of drug interactions through the quantification of the Combination Index (CI). Our findings in MCF-7 and PC-3 cancer cells demonstrated that the combination of these peptides with paclitaxel (PTX) and doxorubicin (DOXO), respectively, is not advantageous over a single treatment with the chemotherapeutic agent. In the case of HT-29 colorectal cancer cells, the combination of P2–P4 with 5-FU resulted in synergistic cytotoxic effects, as predicted by the in silico simulations. Taken together, these findings demonstrate that these CPP6-conjugates can be used as adjuvant agents to increase the delivery of 5-FU into HT-29 colorectal cancer cells. Moreover, these results support the use of in silico approaches for the prediction of the interaction between drugs in combination therapy for cancer." @default.
• W4313502805 created "2023-01-06" @default.
• W4313502805 creator A5003713952 @default.
• W4313502805 creator A5004830875 @default.
• W4313502805 creator A5008456031 @default.
• W4313502805 creator A5038432697 @default.
• W4313502805 creator A5054091339 @default.
• W4313502805 creator A5079186718 @default.
• W4313502805 date "2022-12-21" @default.
• W4313502805 modified "2023-09-29" @default.
• W4313502805 title "Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches" @default.
• W4313502805 cites W1534849470 @default.
• W4313502805 cites W1980441078 @default.
• W4313502805 cites W2015704490 @default.
• W4313502805 cites W2038720675 @default.
• W4313502805 cites W2040426010 @default.
• W4313502805 cites W2052706007 @default.
• W4313502805 cites W2064282122 @default.
• W4313502805 cites W2096439168 @default.
• W4313502805 cites W2120623774 @default.
• W4313502805 cites W2137584261 @default.
• W4313502805 cites W2139436990 @default.
• W4313502805 cites W2149429360 @default.
• W4313502805 cites W2153617834 @default.
• W4313502805 cites W2153936360 @default.
• W4313502805 cites W2164841185 @default.
• W4313502805 cites W2588262749 @default.
• W4313502805 cites W2758156076 @default.
• W4313502805 cites W2944685171 @default.
• W4313502805 cites W3000479750 @default.
• W4313502805 cites W3026323285 @default.
• W4313502805 cites W3096329423 @default.
• W4313502805 cites W3110259941 @default.
• W4313502805 cites W3120202179 @default.
• W4313502805 cites W3158480538 @default.
• W4313502805 cites W3177769843 @default.
• W4313502805 cites W3213075003 @default.
• W4313502805 cites W4200451419 @default.
• W4313502805 cites W4306362565 @default.
• W4313502805 cites W4308909312 @default.
• W4313502805 doi "https://doi.org/10.3390/ijms24010069" @default.
• W4313502805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36613510" @default.
• W4313502805 hasPublicationYear "2022" @default.
• W4313502805 type Work @default.
• W4313502805 citedByCount "2" @default.
• W4313502805 countsByYear W43135028052023 @default.
• W4313502805 crossrefType "journal-article" @default.
• W4313502805 hasAuthorship W4313502805A5003713952 @default.
• W4313502805 hasAuthorship W4313502805A5004830875 @default.
• W4313502805 hasAuthorship W4313502805A5008456031 @default.
• W4313502805 hasAuthorship W4313502805A5038432697 @default.
• W4313502805 hasAuthorship W4313502805A5054091339 @default.
• W4313502805 hasAuthorship W4313502805A5079186718 @default.
• W4313502805 hasBestOaLocation W43135028051 @default.
• W4313502805 hasConcept C104317684 @default.
• W4313502805 hasConcept C112705442 @default.
• W4313502805 hasConcept C126322002 @default.
• W4313502805 hasConcept C178790620 @default.
• W4313502805 hasConcept C181389837 @default.
• W4313502805 hasConcept C185592680 @default.
• W4313502805 hasConcept C202751555 @default.
• W4313502805 hasConcept C2775905019 @default.
• W4313502805 hasConcept C2776694085 @default.
• W4313502805 hasConcept C2776999253 @default.
• W4313502805 hasConcept C2777292972 @default.
• W4313502805 hasConcept C2779281246 @default.
• W4313502805 hasConcept C2779820397 @default.
• W4313502805 hasConcept C2780035454 @default.
• W4313502805 hasConcept C2780456651 @default.
• W4313502805 hasConcept C2781303535 @default.
• W4313502805 hasConcept C3019864225 @default.
• W4313502805 hasConcept C55493867 @default.
• W4313502805 hasConcept C71924100 @default.
• W4313502805 hasConcept C98274493 @default.
• W4313502805 hasConceptScore W4313502805C104317684 @default.
• W4313502805 hasConceptScore W4313502805C112705442 @default.
• W4313502805 hasConceptScore W4313502805C126322002 @default.
• W4313502805 hasConceptScore W4313502805C178790620 @default.
• W4313502805 hasConceptScore W4313502805C181389837 @default.
• W4313502805 hasConceptScore W4313502805C185592680 @default.
• W4313502805 hasConceptScore W4313502805C202751555 @default.
• W4313502805 hasConceptScore W4313502805C2775905019 @default.
• W4313502805 hasConceptScore W4313502805C2776694085 @default.
• W4313502805 hasConceptScore W4313502805C2776999253 @default.
• W4313502805 hasConceptScore W4313502805C2777292972 @default.
• W4313502805 hasConceptScore W4313502805C2779281246 @default.
• W4313502805 hasConceptScore W4313502805C2779820397 @default.
• W4313502805 hasConceptScore W4313502805C2780035454 @default.
• W4313502805 hasConceptScore W4313502805C2780456651 @default.
• W4313502805 hasConceptScore W4313502805C2781303535 @default.
• W4313502805 hasConceptScore W4313502805C3019864225 @default.
• W4313502805 hasConceptScore W4313502805C55493867 @default.
• W4313502805 hasConceptScore W4313502805C71924100 @default.
• W4313502805 hasConceptScore W4313502805C98274493 @default.
• W4313502805 hasIssue "1" @default.
• W4313502805 hasLocation W43135028051 @default.
• W4313502805 hasLocation W43135028052 @default.
• W4313502805 hasLocation W43135028053 @default.

• next